What is InDevR?
InDevR operates at the intersection of biotechnology and manufacturing efficiency, specializing in the development of sophisticated analytical tools for protein characterization. By providing essential infrastructure for vaccine process optimization, the company enables biotherapeutic developers to streamline their research and production workflows. Their product portfolio is specifically engineered to meet the rigorous demands of modern life science research, ensuring that critical medical innovations can be brought to market with greater speed and precision. Beyond its hardware and software solutions, InDevR offers specialized testing and custom services, positioning itself as a comprehensive partner for organizations navigating the complexities of infectious disease research and global health initiatives.
How much funding has InDevR raised?
InDevR has raised a total of $19.3M across 4 funding rounds:
Grant
$2.9M
Series A
$7M
Debt
$350K
Series B
$9M
Grant (2014): $2.9M with participation from National Institute of Allergy and Infectious Diseases
Series A (2019): $7M led by Adjuvant Capital
Debt (2020): $350K supported by PPP
Series B (2023): $9M featuring Adjuvant Capital and BioMérieux Turkey
Key Investors in InDevR
Adjuvant Capital
Adjuvant Capital is a venture capital firm focused on financing innovative life science technologies that address high-burden public health challenges, emphasizing both social and financial returns.
BioMérieux Turkey
A regional branch of a global leader in in vitro diagnostics, focusing on clinical and industrial applications to improve patient health and consumer safety.
National Institute of Allergy and Infectious Diseases
A federal agency dedicated to conducting and supporting research to better understand, treat, and prevent infectious, immunologic, and allergic diseases.
What's next for InDevR?
With the successful closure of this major strategic investment, InDevR is well-positioned to expand its footprint in the global biotherapeutic market. The company is expected to prioritize the scaling of its protein characterization platforms, further integrating its technology into the manufacturing pipelines of major vaccine producers. Future strategic initiatives will likely focus on enhancing the accessibility of these tools in emerging markets, aligning with the mission-driven objectives of its primary backers. As the firm continues to refine its analytical capabilities, it remains a key player in the effort to improve global health outcomes through technological innovation and process excellence.
See full InDevR company page
